INmune Bio, Inc. (NASDAQ: INMB) reported Q1 EPS of ($0.61), $0.08 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $14 thousand versus the consensus estimate of $43 thousand.

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.